QNTM earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -0.35. Updated 2026-07-23.
Quantum BioPharma (QNTM) Research Hub
Quantum BioPharma (QNTM) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.21 USD (-1.34%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.35, market cap 0.01B. This hub links to the full technical, earnings and options research available for QNTM.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 2.21 USD (-1.34%) |
| 52-week range | 2.091 USD – 4.4 USD |
| Trend regime | Range |
| 14-day RSI | 15.6 (Oversold) |
| Trailing P/E | -0.35 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for QNTM
Covered Call on QNTM: how it works, illustrative setup around the real 2.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on QNTM: how it works, illustrative setup around the real 2.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on QNTM: how it works, illustrative setup around the real 2.21 USD price, max profit/loss, breakeven and when to use it. Educational.
QNTM technical analysis: range, last 2.21 USD, RSI 15.6, 52w range 2.091 USD–4.4 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is QNTM in?
Quantum BioPharma (QNTM) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is QNTM in an uptrend or downtrend?
As of 2026-10-26, QNTM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is QNTM's trailing P/E ratio?
QNTM's trailing P/E is -0.35, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does QNTM next report earnings?
QNTM is next scheduled to report earnings on 2026-08-06.